HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 54495

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLYNTiATL   susceptible form
SLYNTiAvL   susceptible form
SLYNTVAvL   susceptible form
SLfNTVATL   susceptible form
SLfNTiAvL   susceptible form
SLfNTVAvL   susceptible form
SLfNTiATL   susceptible form
SLYNsVATL   susceptible form
SLYqTVATL   susceptible form
SLYlTVATL   susceptible form
aLYNTVATL   susceptible form
SLaNTVATL   non-susceptible form
SLYaTVATL   non-susceptible form
SLYNTaATL   diminished response
SLYNTVAaL   diminished response
aLYNTaAaL   non-susceptible form
SLYNvVATL   non-susceptible form
SLYNlVAvL   escape documented in this paper; TCR related mutation
SLYNlVAvL   escape documented in this paper; TCR related mutation
SLYNaVATL   escape documented in this paper; TCR related mutation
SLYNaiATL   escape documented in this paper; TCR related mutation
SLYNlVAvL   escape documented in this paper; TCR related mutation
Epitope Name SL9
Species (MHC/HLA human(A2)

Variant Details

Showing all: 22 variant(s).


Variant ID.  1052
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1053
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAvL
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1054
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAvL
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1055
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible and only very slightly less active than wild type SL9.


Variant ID.  1056
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiAvL
Mutations Y/F V/I T/V
Epitope Location Y3F V6I T8V
HXB2 Location Y79F V82I T84V
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1057
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVAvL
Mutations Y/F T/V
Epitope Location Y3F T8V
HXB2 Location Y79F T84V
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1058
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiATL
Mutations Y/F V/I
Epitope Location Y3F V6I
HXB2 Location Y79F V82I
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1059
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNsVATL
Mutations T/S
Epitope Location T5S
HXB2 Location T81S
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1060
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYqTVATL
Mutations N/Q
Epitope Location N4Q
HXB2 Location N80Q
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1061
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYlTVATL
Mutations N/L
Epitope Location N4L
HXB2 Location N80L
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.


Variant ID.  1062
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTVATL
Mutations S/A
Epitope Location S1A
HXB2 Location S77A
Mutation Type SF: susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible, indistinguishable from the wild type SL9.


Variant ID.  1063
Epitope Seq.  SLYNTVATL
Variant Seq.  SLaNTVATL
Mutations Y/A
Epitope Location Y3A
HXB2 Location Y79A
Mutation Type NSF: non-susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.


Variant ID.  1064
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYaTVATL
Mutations N/A
Epitope Location N4A
HXB2 Location N80A
Mutation Type NSF: non-susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.


Variant ID.  1065
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTaATL
Mutations V/A
Epitope Location V6A
HXB2 Location V82A
Mutation Type DR: diminished response
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL has very low activity.


Variant ID.  1066
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAaL
Mutations T/A
Epitope Location T8A
HXB2 Location T84A
Mutation Type DR: diminished response
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was less active.


Variant ID.  1067
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTaAaL
Mutations S/A V/A T/A
Epitope Location S1A V6A T8A
HXB2 Location S77A V82A T84A
Mutation Type NSF: non-susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.


Variant ID.  1068
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNvVATL
Mutations T/V
Epitope Location T5V
HXB2 Location T81V
Mutation Type NSF: non-susceptible form
Method Chromium-release assay, Sequence
Note This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.


Variant ID.  2224
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAvL
Mutations T/L T/V
Epitope Location T5L T8V
HXB2 Location T81L T84V
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.


Variant ID.  2248
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAvL
Mutations T/L T/V
Epitope Location T5L T8V
HXB2 Location T81L T84V
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.


Variant ID.  2250
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNaVATL
Mutations T/A
Epitope Location T5A
HXB2 Location T81A
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.


Variant ID.  2251
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNaiATL
Mutations T/A V/I
Epitope Location T5A V6I
HXB2 Location T81A V82I
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.


Variant ID.  2252
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAvL
Mutations T/L T/V
Epitope Location T5L T8V
HXB2 Location T81L T84V
Mutation Type E: escape documented in this paper
TCR: TCR related mutation
Method Chromium-release assay, Sequence
Note This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.

References

Martinez-Hackert2006 Erik Martinez-Hackert, Nadia Anikeeva, Spyros A. Kalams, Bruce D. Walker, Wayne A. Hendrickson, and Yuri Sykulev. Structural Basis for Degenerate Recognition of Natural HIV Peptide Variants by Cytotoxic Lymphocytes. J. Biol. Chem., 281(29):20205-20212, 21 Jul 2006. PubMed ID: 16702212. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health